These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22011986)

  • 21. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use.
    Mendes C; Costa AP; Oliveira PR; Tagliari MP; Silva MA
    Pharm Dev Technol; 2013; 18(4):813-20. PubMed ID: 22670721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Freeze dried chitosan/ poly-(glutamic acid) microparticles for intestinal delivery of lansoprazole.
    Singh MN; Yadav HK; Ram M; Shivakumar HG
    Curr Drug Deliv; 2012 Jan; 9(1):95-104. PubMed ID: 21864257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
    Burnett JE; Balkin ER
    Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of the Physical, Chemical and Microbiological Stability of Losartan Potassium 5 mg/mL Extemporaneous Oral Liquid Suspension.
    Foley L; Toney J; Barlow JW; O'Connor M; Fitzgerald-Hughes D; Ramtoola Z
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33435555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-dimensional chromatography method applied to the enantiomeric determination of lansoprazole in human plasma by direct sample injection.
    Gomes RF; Cassiano NM; Pedrazzoli J; Cass QB
    Chirality; 2010 Jan; 22(1):35-41. PubMed ID: 19229958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4.
    Espana B; Joseph-Tornabène F; Jaquet C; Perrot S; Prouillac C
    Int J Pharm Compd; 2020; 24(4):327-336. PubMed ID: 32649306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of buffer and antioxidant on stability of a mercaptopurine suspension.
    Aliabadi HM; Romanick M; Desai S; Lavasanifar A
    Am J Health Syst Pharm; 2008 Mar; 65(5):441-7. PubMed ID: 18281736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients.
    Ren S; Park MJ; Kim A; Lee BJ
    Arch Pharm Res; 2008 Mar; 31(3):406-13. PubMed ID: 18409057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric oral solutions with propranolol hydrochloride for extemporaneous compounding: the formulation and stability study.
    Klovrzová S; Zahálka L; Matysová L; Horák P; Sklubalová Z
    Ceska Slov Farm; 2013 Feb; 62(1):35-9. PubMed ID: 23578266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of an extemporaneously prepared clopidogrel oral suspension.
    Skillman KL; Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2010 Apr; 67(7):559-61. PubMed ID: 20237383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets.
    Sosnowska K; Winnicka K; Czajkowska-Kośnik A
    Acta Pol Pharm; 2009; 66(3):321-6. PubMed ID: 19645333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acido-basic properties of proton pump inhibitors in aqueous solutions.
    Kristl A
    Drug Dev Ind Pharm; 2009 Jan; 35(1):114-7. PubMed ID: 18720145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uneven Distribution of Microgranules in Divided Lansoprazole Tablets.
    Teitelbaum GA; Teitelbaum JE
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):437-9. PubMed ID: 25885882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.